Compare · NVS vs TYRA
NVS vs TYRA
Side-by-side comparison of Novartis AG (NVS) and Tyra Biosciences Inc. (TYRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and TYRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $192.19B, about 381.7x TYRA ($503.4M).
- TYRA has hit the wire 10 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 20 for TYRA).
- Company
- Novartis AG
- Tyra Biosciences Inc.
- Price
- -
- -
- Market cap
- $192.19B
- $503.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 10
- Recent ratings
- 25
- 20
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Tyra Biosciences Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG
- SEC Form S-8 POS filed by Novartis AG
Latest TYRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.
- SEC Form 4 filed by Dable Habib J
- SEC Form 3 filed by new insider Dable Habib J
- SEC Form DEFA14A filed by Tyra Biosciences Inc.
- SEC Form DEF 14A filed by Tyra Biosciences Inc.
- SEC Form 8-K filed by Tyra Biosciences Inc.
- Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
- Guggenheim initiated coverage on Tyra Biosciences with a new price target
- SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.
- Canaccord Genuity initiated coverage on Tyra Biosciences with a new price target